MXPA05007648A - Derivados quimicos que se unen de manera muy especifica a las estructuras de adn en g - cuadruplex y su aplicacion como agente anticanceroso especifico. - Google Patents

Derivados quimicos que se unen de manera muy especifica a las estructuras de adn en g - cuadruplex y su aplicacion como agente anticanceroso especifico.

Info

Publication number
MXPA05007648A
MXPA05007648A MXPA05007648A MXPA05007648A MXPA05007648A MX PA05007648 A MXPA05007648 A MX PA05007648A MX PA05007648 A MXPA05007648 A MX PA05007648A MX PA05007648 A MXPA05007648 A MX PA05007648A MX PA05007648 A MXPA05007648 A MX PA05007648A
Authority
MX
Mexico
Prior art keywords
amide
formula
methyl
products
pyridine
Prior art date
Application number
MXPA05007648A
Other languages
English (en)
Spanish (es)
Inventor
Augustin Hittinger
Patrick Mailliet
Jean-Louis Mergny
Thomas Caulfield
Herve Bouchard
Eliane Mandine
Lionel Guittat
Jeanfrancois Riou
Dennis Gomez
Chafke Belmokhtar
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MXPA05007648A publication Critical patent/MXPA05007648A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA05007648A 2003-02-07 2004-02-05 Derivados quimicos que se unen de manera muy especifica a las estructuras de adn en g - cuadruplex y su aplicacion como agente anticanceroso especifico. MXPA05007648A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301478A FR2850970B1 (fr) 2003-02-07 2003-02-07 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
PCT/FR2004/000260 WO2004072027A2 (fr) 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique

Publications (1)

Publication Number Publication Date
MXPA05007648A true MXPA05007648A (es) 2006-12-15

Family

ID=32731875

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007648A MXPA05007648A (es) 2003-02-07 2004-02-05 Derivados quimicos que se unen de manera muy especifica a las estructuras de adn en g - cuadruplex y su aplicacion como agente anticanceroso especifico.

Country Status (8)

Country Link
EP (1) EP1603898A2 (https=)
JP (1) JP2006518726A (https=)
AU (1) AU2004210753A1 (https=)
BR (1) BRPI0407320A (https=)
CA (1) CA2514105A1 (https=)
FR (1) FR2850970B1 (https=)
MX (1) MXPA05007648A (https=)
WO (1) WO2004072027A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
WO2008032324A2 (en) * 2006-09-14 2008-03-20 Ramot At Tel Aviv University Ltd. Combination therapy for tumoral disease treatment
GB0706932D0 (en) * 2007-04-10 2007-05-16 Univ London Pharmacy Ureylene derivatives
WO2009040819A2 (en) 2007-09-25 2009-04-02 Ramot At Tel Aviv University Ltd. DOWN-REGULATION OF MORTALIN BY siRNA
CN101889210B (zh) 2008-05-27 2014-12-10 松下电器产业株式会社 G-quadruplex检测方法、形成G-quadruplex的DNA的检测方法以及端粒酶活性测定方法
JP4510929B1 (ja) 2009-04-09 2010-07-28 パナソニック株式会社 テロメラーゼ反応阻害方法およびそれに用いられるテロメラーゼ反応阻害剤
CN108066341B (zh) * 2016-11-10 2020-10-30 中国科学院化学研究所 化合物在制备抗癌药物中的用途
CN108066340B (zh) * 2016-11-10 2020-10-27 中国科学院化学研究所 药物组合物
WO2018211148A1 (en) * 2017-05-19 2018-11-22 Universite De Bretagne Occidentale Bisquinolium derivatives for preventing or treating ebv-related cancers
CN113272294A (zh) * 2018-08-24 2021-08-17 雅典学院生物医学研究基金会 2,6-双(((1h-苯并[d]咪唑-2-基)硫)甲基)吡啶和n2,n6-二苄基吡啶-2,6-二甲酰胺衍生物以及相关化合物作为磷酸肌醇3-激酶(pi3k)抑制剂用于治疗癌症

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK7402002A3 (en) * 1999-11-29 2002-11-06 Aventis Pharma Sa Arylamine derivatives and their use as anti-telomerase agent
FR2819255B1 (fr) * 2001-01-09 2003-02-28 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
FR2821355A1 (fr) * 2001-02-23 2002-08-30 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
CO5380035A1 (es) * 2001-03-23 2004-03-31 Aventis Pharma Sa Derivados quimicos y su aplicacion como agente antitelomerasa
WO2002096903A2 (fr) * 2001-05-28 2002-12-05 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase

Also Published As

Publication number Publication date
FR2850970B1 (fr) 2006-07-07
WO2004072027A2 (fr) 2004-08-26
AU2004210753A1 (en) 2004-08-26
WO2004072027A3 (fr) 2004-09-23
JP2006518726A (ja) 2006-08-17
EP1603898A2 (fr) 2005-12-14
BRPI0407320A (pt) 2006-02-21
FR2850970A1 (fr) 2004-08-13
CA2514105A1 (fr) 2004-08-26

Similar Documents

Publication Publication Date Title
EP2597955B1 (en) Quinoline derivatives and melk inhibitors containing the same
AU699043B2 (en) Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
CN117730075A (zh) 一种吡唑衍生物,其制备方法和在药学上的应用
US20050080096A1 (en) Condensed heterocyclic compounds
CN102933578B (zh) 氰基喹啉衍生物
US20090226411A1 (en) Chemical derivatives and their application as antitelomerase agents
JP2012158611A (ja) 2−アミノ−7,8−ジヒドロ−6H−ピリド[4,3−d]ピリミジン−5−オン
US20040138257A1 (en) Chemical derivatives and their application as antitelomerase agent
CN108947879B (zh) Prmt i型抑制剂及其制备方法和用途
Godlewska et al. Biological evaluation of ω-(dialkylamino) alkyl derivatives of 6H-indolo [2, 3-b] quinoline-novel cytotoxic DNA topoisomerase II inhibitors
MXPA05007648A (es) Derivados quimicos que se unen de manera muy especifica a las estructuras de adn en g - cuadruplex y su aplicacion como agente anticanceroso especifico.
JP2004524349A (ja) 化学的誘導体および抗テロメラーゼ剤としてのその使用
WO1999040093A2 (en) Synthesis of quinobenzoxazine analogues with topoisomerase ii and quadruplex interactions for use as antineoplastic agents
Zhang et al. Syntheses and evaluation of acridone-naphthalimide derivatives for regulating oncogene PDGFR-β expression
JP6607962B2 (ja) β−グルクロニダーゼの阻害のためのピラゾロ[4,3−c]キノリン誘導体
US7179816B2 (en) Chemical derivatives and their application as antitelomerase agents
US20070232572A1 (en) Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
KR20140044790A (ko) 피페라진디온 화합물
CN118772164A (zh) 蛋白精氨酸甲基转移酶抑制剂
WO1998057949A1 (en) Novel tricyclic sulfonamide inhibitors of farnesyl-protein transferase
MXPA02006749A (es) Derivados de pirazoloquinolinona como inhibidores de proteina quinasa c.
AU2002229859B2 (en) Chemical derivatives and their use as anti-telomerase agent
RU2527459C1 (ru) Новые лиганды g-квадруплексов на основе гетероаренантрацендионов, ингибирующие рост опухолевых клеток
US20030013711A1 (en) Chemical derivatives and their application as antitelomerase agents
WO2017192228A1 (en) Pak1 inhibitors and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal